RNA Targeting Small Molecules Therapeutics Market by Type of Target Molecule (Cap Binding Complex, CDKL5, Dystrophin Protein, Era, G542X, MNK1 / MNK2, PAX6 gene, SMN2), Type of Approach (Indirect RNA Targeting- Epitranscriptomics, mRNA Translation Modulat

RNA Targeting Small Molecules Therapeutics Market by Type of Target Molecule (Cap Binding Complex, CDKL5, Dystrophin Protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2), Type of Approach (Indirect RNA Targeting- Epitranscriptomics, mRNA Translation Modulation, RNA Splicing Modification), Target Indication (Aniridia, Breast Cancer, Castrate-resistant Prostate Cancer, Colorectal Cancer, Crohn Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Dravet Syndrome, Epilepsy, HIV Infections, Impaired Renal Function, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Spinal Muscular Atrophy, Ulcerative Colitis), Target Therapeutic Area (Autoimmune Disorders, Genetic Disorders, Infectious Disorders, Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Ophthalmic Disorders, Rare Disorders, Renal Disorders, Respiratory Disorders), Route of Administration (Oral and Subcutaneous Injection) and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

Small molecule products presently dominate the overall pharmaceutical market, representing around 80% of the total pipeline candidates. In fact, in 2020, the USFDA approved 55 drugs, of which, over 65% were small molecule therapeutics. , It is worth noting that majority of these drugs were conventionally developed to target proteins. However, reports suggest that merely 2% of the human genome is responsible for coding for proteins. Hence, the pharmaceutical industry is now focused on evaluating previously untapped targets, such as non-coding DNA and RNA; the latter molecules are expected to correspond to ~70% of the unknown portion of the human genome. , In recent past, RNA’s limitless potential as a target for small molecules, against a wide range of indications (both oncological and non-oncological), has been recognized. Specifically, a variety of small molecules that affect RNA function have been discovered. Further, many RNA riboswitch regulatory elements (capable of binding to a variety of small molecule metabolites and control gene expression) and small molecule antibiotics (having the ability to bind to ribosomal RNA and interfere with translation) have been identified. Consequently, drug developers are experimenting with RNA modification, RNA translation, RNA splicing, indirect RNA targeting (epitranscriptomics), and other ways to target RNA with small molecules.

Currently, over 100 small molecule therapeutics, targeting naïve RNA, are under development. Several experiments and clinical trials focused on RNA targeting antisense oligonucleotides (many of which have received regulatory approval), as well as preclinical studies for synthetic RNAs, which can redirect cellular RNA interference (RNAi) machinery or activate CRISPR-based systems, have demonstrated strong proof of principle for RNA targeting drugs. Moreover, a number of industry players (mostly small firms and start-ups) have developed their proprietary technologies for direct and indirect RNA targeting. Additionally, in the past five years, more than USD 800 million was invested in companies engaged in the development of RNA targeting small molecule therapeutics (primarily those developing candidates against oncological disorders). Many big pharma players, such as Pfizer, Novartis and Takeda Pharmaceutical, have also actively supported the initiatives taken by such drug developers, by making lucrative investments. Driven by encouraging clinical trial results, strategic collaborations and initiatives undertaken to expand expanding intellectual capital, this emerging market is expected to grow at a steady pace in the foreseen future.

The “RNA Targeting Small Molecules Therapeutics Market by Type of Target Molecule (Cap Binding Complex, CDKL5, Dystrophin Protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2), Type of Approach (Indirect RNA Targeting- Epitranscriptomics, mRNA Translation Modulation, RNA Splicing Modification), Target Indication (Aniridia, Breast Cancer, Castrate-resistant Prostate Cancer, Colorectal Cancer, Crohn Disease, Cystic Fibrosis, Duchenne Muscular Dystrophy, Dravet Syndrome, Epilepsy, HIV Infections, Impaired Renal Function, Non-Small Cell Lung Cancer, Rheumatoid Arthritis, Spinal Muscular Atrophy, Ulcerative Colitis), Target Therapeutic Area (Autoimmune Disorders, Genetic Disorders, Infectious Disorders, Inflammatory Disorders, Neurological Disorders, Oncological Disorders, Ophthalmic Disorders, Rare Disorders, Renal Disorders, Respiratory Disorders), Route of Administration (Oral and Subcutaneous Injection) and Region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of RNA targeting small molecule therapeutics in the pharmaceutical industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:
 A detailed overview of the current market landscape of RNA targeting small molecule therapeutics, including information on phase of development (clinical and preclinical), target disease indication(s), therapeutic area (non-oncological disorders and oncological disorders), target molecule (BMI1, cap binding complex, eLF4A, MNK1 / MNK2, VEGF, others), type of approach (indirect RNA targeting – epitranscriptomics, mRNA translation modulation, RNA splicing modification) and route of administration (intravenous, subcutaneous, and oral). In addition, it highlights the developers of these novel therapeutics, along with information on their year of establishment, company size (in terms of employee count), location of headquarters and number of proprietary drug candidates.
 An in-depth analysis of the company competitiveness and investment landscape, including a bubble analysis comparing the key players engaged in the domain of RNA targeting small molecules, based on several relevant parameters (such as company experience, pipeline strength, partnership activity, funding activity, patents filed and company size) and a multivariate representation illustrating the start-ups and investment activity based on various multiple parameters (such as funding type, therapeutic area and amount invested).
 Elaborate profiles of key players engaged in the development of RNA targeting small molecule therapeutics. Each profile features a brief overview of the company, recent developments and an informed future outlook.
 An analysis of the recent collaborations and partnerships that have been inked between various stakeholders in this domain, during the period between 2017 and 2021, covering R&D agreements, clinical trial agreements, acquisitions, licensing agreements and product development agreements.
 An analysis of the investments made, during the period between 2015 and 2021, including grant, seed financing, venture capital financing, initial public offering (IPO), debt financing and other equity, in companies that are engaged in the development of RNA targeting small molecule therapeutics.

One of the key objectives of the report was to estimate the existing size and the future opportunity associated with the RNA targeting small molecules therapeutics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of target molecule (cap binding complex, CDKL5, dystrophin protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2) [B] type of approach (indirect RNA targeting- epitranscriptomics, mRNA translation modulation, RNA splicing modification) [C] target indication (aniridia, breast cancer, castrate-resistant prostate cancer, colorectal cancer, Crohn disease, cystic fibrosis, Duchenne muscular dystrophy, Dravet syndrome, epilepsy, HIV infections, impaired renal function, non-small cell lung cancer, rheumatoid arthritis, spinal muscular atrophy, ulcerative colitis) [D] target therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, inflammatory disorders, neurological disorders, oncological disorders, ophthalmic disorders, rare disorders, renal disorders, respiratory disorders), [E] route of administration (oral and subcutaneous injection) and [E] region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three forecast scenarios, portraying the conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):
 Clara Assouline (Business Development, Anima Biotech)
 Dominique Cheneval (President / Co-Founder, Novation Pharmaceuticals)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the key players engaged in the development of RNA targeting small molecule therapeutics?
 What are the current investment trends in this field?
 Which are the key therapeutic areas for which RNA targeting small molecule therapies are being developed?
 What are the different technological approaches adopted by various players for the development of RNA targeting small molecule therapeutics?
 What type of partnership models are most commonly adopted by stakeholders engaged in this domain?
 What is the relative competitiveness of different RNA targeting small molecule therapeutics developers engaged in this market?
 How is the current and future market opportunity likely to be distributed across key market segments?

CHAPTER OUTLINES

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of RNA targeting small molecule therapeutics market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to RNA targeting small molecule therapeutics. The chapter also features information on approaches used to target RNA with small molecules including mRNA translation regulation, RNA splicing modification, direct and indirect RNA targeting (epitranscriptomics). It also includes a list of small molecules targeting RNA, emerging technologies in this domain and future perspectives.

Chapter 4 includes information on more than 100 RNA targeting small molecule therapeutics candidates. It features a detailed analysis on current market landscape of RNA targeting small molecule therapeutics, including information on phase of development (clinical and preclinical), target disease indication(s), therapeutic area (non-oncological disorders and oncological disorders), target molecule (BMI1, cap binding complex, eLF4A, MNK1 / MNK2, VEGF, others), type of approach (indirect RNA targeting – epitranscriptomics, mRNA translation modulation, RNA splicing modification) and route of administration (intravenous, subcutaneous, and oral). The chapter also features developers’ landscape, along with information on their year of establishment, company size (very small, small, mid-sized or large), location of headquarters and number of proprietary drug candidates.

Chapter 5 presents a detailed company competitiveness analysis, including a bubble analysis comparing the key players engaged in the domain of RNA targeting small molecules, based on several relevant parameters (such as company experience, pipeline strength, partnership activity, funding activity, patents filed and company size). In addition, it features a multivariate representation illustrating the start-ups and investment activity based on various parameters (such as funding type, amount invested and key players).

Chapter 6 features elaborate profiles of prominent players engaged in development of RNA targeting small molecule therapeutics. Each profile features a brief overview of the company, details related to its respective drug candidates, recent developments and an informed future outlook.

Chapter 7 presents an in-depth analysis on recent collaborations and partnerships that have been inked by stakeholders in this domain, during the period 2017-2021, covering R&D agreements, clinical trial agreements, acquisitions, licensing agreements and product development agreements.

Chapter 8 presents an insightful analysis of funding activity of industry players engaged in the development of RNA targeting small molecule therapeutics during the period between 2015 and 2021, including type of funding (grant, seed financing, venture capital financing, initial public offering (IPO), debt financing and other equity) and amount of funding. Further, the chapter also highlights investment information on focus therapeutic areas, phase of development of drug candidates, geography and key investors.

Chapter 9 presents a detailed market forecast analysis, highlighting the current market size and the future growth potential associated with the RNA targeting small molecules therapeutics market, during the period 2021-2030. The chapter also provides the likely distribution of the current and forecasted opportunity based on type of target molecule (cap binding complex, CDKL5, dystrophin protein, Erα, G542X, MNK1 / MNK2, PAX6 gene, SMN2), type of approach (indirect RNA targeting- epitranscriptomics, mRNA translation modulation, RNA splicing modification), target indication (aniridia, breast cancer, castrate-resistant prostate cancer, colorectal cancer, Crohn disease, cystic fibrosis, Duchenne muscular dystrophy, Dravet syndrome, epilepsy, HIV infections, impaired renal function, non-small cell lung cancer, rheumatoid arthritis, spinal muscular atrophy, ulcerative colitis), target therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, inflammatory disorders, neurological disorders, oncological disorders, ophthalmic disorders, rare disorders, renal disorders, respiratory disorders), route of administration (oral and subcutaneous injection) and region (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 10 summarizes the entire report. It represents key takeaways and summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 11 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Clara Assouline (Business Development, Anima Biotech) and Dominique Cheneval (President / Co-Founder, Novation Pharmaceuticals).

Chapter 12 is an appendix, which provides tabulated data and numbers for all figures provided in the report.

Chapter 13 is an appendix, which comprises of the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies and organizations have been mentioned in the report:
1. AbbVie Ventures
2. Abingworth
3. Abivax
4. AC Immune
5. Accel-Rx Health Sciences Accelerator
6. Accent Therapeutics
7. Advent Life Sciences
8. Agent Capital
9. Alexandria Venture Investments
10. ALS Society of Canada
11. Altitude Life Science Ventures
12. Amgen Ventures
13. Anima Biotech
14. Arrakis Therapeutics
15. Astellas Venture Management
16. AstraZeneca
17. Atlas Venture
18. AviTx
19. BDC Venture Capital
20. Biogen
21. BioMed Ventures
22. Brain Canada
23. Bristol-Myers Squibb
24. Cambridge Innovation Capital
25. Canaan Partners
26. Catalyst Investors
27. Celgene
28. CHDI Foundation
29. Cystic Fibrosis Foundation
30. Droia Ventures
31. DSC Investment
32. EcoR1 Capital
33. eFFECTOR Therapeutics
34. Eli Lilly
35. Eloxx Pharmaceuticals
36. Evotec
37. Flatiron Health
38. Forbion Capital Partners
39. Foundation Medicine
40. FutureNeuro
41. Genentech
42. Good Growth Capital
43. Gotham Therapeutics
44. GreatPoint Ventures
45. GV
46. H3 Biomedicine
47. Hatteras Venture Partners
48. HBM Healthcare Investments
49. Illumina Ventures
50. Imperial Innovations
51. ImStar Therapeutics
52. Innovate UK
53. IP Group
54. Johnson & Johnson Innovation
55. Korea Investment Partners
56. Kreos Capital
57. Longwood Fund
58. Life Sciences Partners
59. M Ventures
60. Massachusetts General Hospital
61. Merck
62. Mission Bay Capital
63. Mitsubishi UFJ Capital
64. MP Healthcare Venture Management
65. MPM Capital
66. Nextech Invest
67. Novartis Venture Fund
68. Novation Pharmaceuticals
69. NS Investment
70. Omega Funds
71. OPKO Health
72. Origenis
73. Osage University Partners
74. Pappas Capital
75. PCAS
76. Pfizer
77. Pontifax Venture Capital
78. Precipio
79. Reaction Biology
80. PTC Therapeutics
81. Quark Venture
82. Reborna Biosciences
83. Reily and Associates
84. Ribometrix
85. Roche
86. Saverna Therapeutics
87. Sectoral Asset Management
88. Selvita
89. Sevion Therapeutics
90. ShangPharma Innovation
91. Skyhawk Therapeutics
92. Sofinnova Partners
93. Spinal Muscular Atrophy Foundation
94. SR One Capital Management
95. STORM Therapeutics
96. SV Health Investors
97. Symeres
98. Taiho Ventures
99. Takeda Pharmaceutical
100. The Column Group
101. The Dementia Discovery Fund (DDF)
102. The Mark Foundation for Cancer Research
103. Touchstone Innovations
104. Twentyeight-Seven Therapeutics
105. U.S. Venture Partners
106. University of Pennsylvania
107. venBio
108. Versant Ventures
109. Vertex Pharmaceuticals
110. Virtusa
111. WuXi AppTec Venture Fund
112. Zikani Therapeutics
113. ZoBio

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. RNA Targeting Therapeutics
3.3. RNA Targets for Small Molecules
3.4. Approaches Used to Target RNA
3.4.1. mRNA Translation Regulation
3.4.2. RNA Splicing Modification
3.4.3. RNA Targeting
3.4.3.1. Direct RNA Targeting
3.4.3.2 . Indirect RNA Targeting (Epitranscriptomics)
3.5. Emerging Technologies
3.6. Future Perspective
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. RNA Targeting Small Molecule Therapeutics: Clinical-stage and Marketed Drug Candidates
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication(s)
4.2.3. Analysis by Phase of Development and Target Disease Indication(s)
4.2.4. Analysis by Therapeutic Area
4.2.5. Analysis by Phase of Development and Therapeutic Area
4.2.6. Analysis by Target Molecule
4.2.7. Analysis by Phase of Development and Target Molecule
4.2.8. Analysis by Type of Approach
4.2.9. Analysis by Phase of Development and Type of Approach
4.2.10. Analysis by Route of Administration
4.3. RNA Targeting Small Molecule Therapeutics: Preclinical-stage Drug Candidates
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Disease Indication(s)
4.3.3. Analysis by Phase of Development and Target Disease Indication(s)
4.3.4. Analysis by Therapeutic Area
4.3.5. Analysis by Phase of Development and Therapeutic Area
4.3.6. Analysis by Target Molecule
4.3.7. Analysis by Phase of Development and Target Molecule
4.3.8. Analysis by Type of Approach
4.3.9. Analysis by Phase of Development and Type of Approach
4.4. RNA Targeting Small Molecule Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Most Active Players: Analysis by Number of Proprietary Drug Candidates
5. COMPANY COMPETITIVENESS AND INVESTMENTS LANDSCAPE
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. RNA Targeting Small Molecule Therapeutics Developers: Competitiveness Analysis
5.4. RNA Targeting Small Molecule Therapeutics Developers: Investment Analysis
5.5. Short Profiles of Top Five Players
5.5.1. PTC Therapeutics
5.5.2. AC Immune
5.5.3. Skyhawk Therapeutics
5.5.4. Abivax
5.5.5. eFFECTOR Therapeutics
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Abivax
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook
6.3. AC immune
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook
6.4. Arrakis Therapeutics
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook
6.5. eFFECTOR Therapeutics
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook
6.6. Eloxx Pharmaceuticals
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook
6.7. H3 Biomedicine
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook
6.8. PTC Therapeutics
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook
6.9. Ribometrix
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook
6.10. Skyhawk Therapeutics
6.10.1. Company Overview
6.10.2. Recent Developments and Future Outlook
6.11. STORM Therapeutics
6.11.1. Company Overview
6.11.2. Recent Developments and Future Outlook
7. RECENT COLLABORATIONS AND PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. RNA Targeting Small Molecule Therapeutics: Recent Partnerships
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Year and Type of Partnership
7.3.4. Analysis by Target Indication(s)
7.3.5. Analysis by Type of Partnership and Target Indication(s)
7.3.6. Analysis by Therapeutic Area
7.3.7. Analysis by Type of Partnership and Therapeutic Area
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.3.9. Regional Analysis
7.3.9.1. Country-wise Distribution
7.3.9.2. Region-wise Distribution
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Type of Funding
8.3. RNA Targeting Small Molecule Therapeutics: Funding and Investment Analysis
8.3.1. Cumulative Year-wise Trend, 2015-2021
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Phase of Development
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Region
8.3.6.1. Most Active Players: Analysis by Number of Funding Instances
8.3.6.2. Most Active Players: Analysis by Amount of Funding
8.3.7. Most Active Investors: Distribution by Number of Funding Instances
8.4. Concluding Remarks
9. MARKET SIZING AND OPPORTUNITY ANALYSIS
9.1. Chapter Overview
9.2. Scope and Limitations
9.3. Key Assumptions and Forecast Methodology
9.4. Global RNA Targeting Small Molecule Therapeutics Market, 2021-2030
9.4.1. RNA Targeting Small Molecule Therapeutics Market: Analysis by Target Disease Indication, 2021 and 2030
9.4.1.1. RNA Targeting Small Molecule Therapeutics Market for Aniridia, 2021-2030
9.4.1.2. RNA Targeting Small Molecule Therapeutics Market for Breast Cancer, 2021-2030
9.4.1.3. RNA Targeting Small Molecule Therapeutics Market for Castrate-resistant Prostate Cancer, 2021-2030
9.4.1.4. RNA Targeting Small Molecule Therapeutics Market for Colorectal Cancer, 2021-2030
9.4 1.5. RNA Targeting Small Molecule Therapeutics Market for Crohn Disease, 2021-2030
9.4.1.6. RNA Targeting Small Molecule Therapeutics Market for Cystic Fibrosis, 2021-2030
9.4.1.7. RNA Targeting Small Molecule Therapeutics Market for Duchenne Muscular Dystrophy, 2021-2030
9.4 1.8. RNA Targeting Small Molecule Therapeutics Market for Dravet Syndrome, 2021-2030
9.4.1.9. RNA Targeting Small Molecule Therapeutics Market for Epilepsy, 2021-2030
9.4.1.10 RNA Targeting Small Molecule Therapeutics Market for HIV Infections, 2021-2030
9.4.1.11 RNA Targeting Small Molecule Therapeutics Market for Impaired Renal Function, 2021-2030
9.4.1.12. RNA Targeting Small Molecule Therapeutics Market for Non-Small Cell Lung Cancer, 2021-2030
9.4 1.13 RNA Targeting Small Molecule Therapeutics Market for Rheumatoid Arthritis, 2021-2030
9.4 1.14 RNA Targeting Small Molecule Therapeutics Market for Spinal Muscular Atrophy, 2021-2030
9.4 1.15 RNA Targeting Small Molecule Therapeutics Market for Ulcerative Colitis, 2021-2030
9.4.2. RNA Targeting Small Molecule Therapeutics Market: Analysis by Key Therapeutic Areas, 2021 and 2030
9.4.2.1. RNA Targeting Small Molecule Therapeutics Market for Autoimmune Disorders, 2021-2030
9.4.2.2. RNA Targeting Small Molecule Therapeutics Market for Genetic Disorders, 2021-2030
9.4.2.3. RNA Targeting Small Molecule Therapeutics Market for Inflammatory Disorders, 2021-2030
9.4.2.4. RNA Targeting Small Molecule Therapeutics Market for Infectious Disorders, 2021-2030
9.4.2.5. RNA Targeting Small Molecule Therapeutics Market for Neurological Disorders, 2021-2030
9.4.2.6. RNA Targeting Small Molecule Therapeutics Market for Oncological Disorders, 2021-2030
9.4.2.7. RNA Targeting Small Molecule Therapeutics Market for Ophthalmic Disorders, 2021-2030
9.4.2.8. RNA Targeting Small Molecule Therapeutics Market for Rare Disorders, 2021-2030
9.4.2.9. RNA Targeting Small Molecule Therapeutics Market for Renal Disorders, 2021-2030
9.4.2.10. RNA Targeting Small Molecule Therapeutics Market for Respiratory Disorders, 2021-2030
9.4.3. RNA Targeting Small Molecule Therapeutics Market: Analysis by Target Molecule, 2021 and 2030
9.4.3.1. RNA Targeting Small Molecule Therapeutics Market for CDKL5, 2021-2030
9.4.3.2. RNA Targeting Small Molecule Therapeutics Market for Cap Binding Complex, 2021-2030
9.4.3.3. RNA Targeting Small Molecule Therapeutics Market for Dystrophin Protein, 2021-2030
9.4.3.4. RNA Targeting Small Molecule Therapeutics Market for Estrogen Receptor Alpha, 2021-2030
9.4.3.5. RNA Targeting Small Molecule Therapeutics Market for G542X, 2021-2030
9.4.3.6. RNA Targeting Small Molecule Therapeutics Market for MNK1 / MNK2, 2021-2030
9.4.3.7. RNA Targeting Small Molecule Therapeutics Market for PAX6 Gene, 2021-2030
9.4.3.8. RNA Targeting Small Molecule Therapeutics Market for SMN2, 2021-2030
9.4.4. RNA Targeting Small Molecule Therapeutics Market: Analysis by Route of Administration, 2021 and 2030
9.4.4.1. RNA Targeting Small Molecule Therapeutics Market for Oral Drugs, 2021-2030
9.4.4.2. RNA Targeting Small Molecule Therapeutics Market for Subcutaneous Injections, 2021-2030
9.4.5. RNA Targeting Small Molecule Therapeutics Market: Analysis by Geography, 2021 and 2030
9.4.5.1. RNA Targeting Small Molecule Therapeutics Market in North America, 2021-2030
9.4.5.2. RNA Targeting Small Molecule Therapeutics Market in Europe, 2021-2030
9.4.5.3. RNA Targeting Small Molecule Therapeutics Market in Asia, 2021-2030
9.4.5.4. RNA Targeting Small Molecule Therapeutics Market in MENA, 2021-2030
9.4.5.5. RNA Targeting Small Molecule Therapeutics Market in Latin America, 2021-2030
9.4.5.6. RNA Targeting Small Molecule Therapeutics Market in Rest of the World, 2021-2030
9.4.6. RNA Targeting Small Molecule Therapeutics Market: Drug-wise Sales Forecast
9.4.6.1. Translarna (Ataluren, PTC127), PTC Therapeutics
9.4.6.1.1. Target Patient Population
9.4.6.1.2. Sales Forecast
9.4.6.1.3. Net Present Value
9.4.6.1.4. Value Creation Analysis
9.4.6.2 Risdiplam, PTC Therapeutics
9.4.6.2.1. Target Patient Population
9.4.6.2.2. Sales Forecast
9.4.6.2.3. Net Present Value
9.4.6.4.4. Value Creation Analysis
9.4.6.3. Tomivosertib (eFT508), eFFECTOR Therapeutics
9.4.6.3.1. Target Patient Population
9.4.6.3.2. Sales Forecast
9.4.6.3.3. Net Present Value
9.4.6.3.4. Value Creation Analysis
9.4.6.4. ELX-02, Eloxx Pharmaceuticals
9.4.6.4.1. Target Patient Population
9.4.6.4.2. Sales Forecast
9.4.6.4.3. Net Present Value
9.4.6.4.4. Value Creation Analysis
9.4.6.5. H3B-6545, H3 Biomedicine
9.4.6.5.1. Target Patient Population
9.4.6.5.2. Sales Forecast
9.4.6.5.3. Net Present Value
9.4.6.5.4. Value Creation Analysis
9.4.6.6. Translarna (Ataluren, PTC124), PTC Therapeutics
9.4.6.6.1. Target Patient Population
9.4.6.6.2. Sales Forecast
9.4.6.6.3. Net Present Value
9.4.6.6.4. Value Creation Analysis
9.4.6.7. ABX464 (Monotherapy), Abivax
9.4.6.7.1. Target Patient Population
9.4.6.7.2. Sales Forecast
9.4.6.7.3. Net Present Value
9.4.6.7.4. Value Creation Analysis
9.4.6.8. ABX464 and Methotrexate, Abivax
9.4.6.8.1. Target Patient Population
9.4.6.8.2. Sales Forecast
9.4.6.8.3. Net Present Value
9.4.6.8.4. Value Creation Analysis
9.5. Concluding Remarks
10. CONCLUSION
11. EXECUTIVE INSIGHTS
11.1. Chapter Overview
11.2. Novation Pharmaceutials
11.2.1. Company Overview
11.2.2. Dominique Cheneval, President / Co-Founder
11.3. Anima Biotech
11.3.1. Company Overview
11.3.2. Clara Assouline, Business Development
12. APPENDIX 1: TABULATED DATA
13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION
LIST OF FIGURES
Figure 4.1 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development
Figure 4.2 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.3 RNA Targeting Small Molecule Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.4 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Therapeutic Area
Figure 4.5 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Figure 4.6 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Target Molecule
Figure 4.7 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development and Target Molecule
Figure 4.8 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Type of Approach
Figure 4.9 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development and Type of Approach
Figure 4.10 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Route of Administration
Figure 4.11 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Figure 4.12 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Figure 4.13 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Figure 4.14 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Figure 4.15 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Figure 4.16 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Molecule
Figure 4.17 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Figure 4.18 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Approach
Figure 4.19 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Type of Approach
Figure 4.20 RNA Targeting Small Molecule Therapeutics Developers: Distribution by Year of Establishment
Figure 4.21 RNA Targeting Small Molecule Therapeutics Developers: Distribution by Company Size
Figure 4.22 RNA Targeting Small Molecule Therapeutics Developers: Distribution by Location of Headquarters
Figure 4.23 Leading Developers: Analysis by Number of Proprietary Drug Candidates
Figure 5.1 RNA Targeting Small Molecule Therapeutics Developers: Competitiveness Analysis
Figure 5.2 RNA Targeting Small Molecule Therapeutics Developers: Investment Analysis
Figure 7.1 Recent Collaborations and Partnerships: Cumulative Year-Wise Trend, 2017 – 2021 (till May)
Figure 7.2 Recent Collaborations and Partnerships: Distribution by Type of Partnership
Figure 7.3 Recent Collaborations and Partnerships: Distribution by Year and Type of Partnership
Figure 7.4 Recent Collaborations and Partnerships: Distribution by Type of Target Indication(s)
Figure 7.5 Recent Collaborations and Partnerships: Distribution by Type of Partnership and Target Indication(s)
Figure 7.6 Recent Collaborations and Partnerships: Distribution by Therapeutic Area
Figure 7.7 Recent Collaborations and Partnerships: Distribution by Type of Partnership and Therapeutic Area
Figure 7.8 Recent Collaborations and Partnerships: Distribution by Number of Partnerships
Figure 7.9 Recent Collaborations and Partnerships: Distribution by Partner Headquarters
Figure 7.10 Recent Collaborations and Partnerships: Country-wise Distribution
Figure 7.11 Recent Collaborations and Partnerships: Region-wise Distribution
Figure 8.1 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015 - 2021
Figure 8.2 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2015-2021
Figure 8.3 Funding and Investment Analysis: Distribution by Type of Funding, 2015-2021
Figure 8.4 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding, 2015-2021
Figure 8.5 Funding and Investment Analysis: Distribution of Total Amount Invested (USD Million) by Type of Funding, 2015-2021
Figure 8.6 Funding and Investment Analysis: Summary of Amount Invested, 2015-2021
Figure 8.7 Funding and Investment Analysis: Distribution by Therapeutic Area, 2015-2021
Figure 8.8 Funding and Investment Analysis: Distribution of Total Amount Invested by Therapeutic Area, 2015-2021 (USD Million)
Figure 8.9 Funding and Investment Analysis: Distribution of Total Amount Invested by Phase of Development, 2015-2021 (USD Million)
Figure 8.10 Funding and Investment Analysis: Distribution by Region
Figure 8.11 Funding and Investment Analysis: Distribution of Total Amount Invested by Region, 2015-2021 (USD Million)
Figure 8.12 Most Active Players: Distribution by Number of Funding Instances, 2015-2021
Figure 8.13 Most Active Players: Distribution by Amount Raised (USD Million), 2015-2021
Figure 8.14 Most Active Investors: Distribution by Number of Funding Instances
Figure 8.15 Funding and Investment Analysis: Concluding Remarks
Figure 9.1 Global RNA Targeting Small Molecule Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Figure 9.2 RNA Targeting Small Molecule Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
Figure 9.3 RNA Targeting Small Molecule Therapeutics Market for Aniridia, 2021-2030 (USD Million)
Figure 9.4 RNA Targeting Small Molecule Therapeutics Market for Breast Cancer, 2021-2030 (USD Million)
Figure 9.5 RNA Targeting Small Molecule Therapeutics Market for Castrate-resistant Prostate Cancer, 2021-2030 (USD Million)
Figure 9.6 RNA Targeting Small Molecule Therapeutics Market for Colorectal Cancer, 2021-2030 (USD Million)
Figure 9.7 RNA Targeting Small Molecule Therapeutics Market for Crohn Disease, 2021-2030 (USD Million)
Figure 9.8 RNA Targeting Small Molecule Therapeutics Market for Cystic Fibrosis, 2021-2030 (USD Million)
Figure 9.9 RNA Targeting Small Molecule Therapeutics Market for Duchenne Muscular Dystrophy, 2021-2030 (USD Million)
Figure 9.10 RNA Targeting Small Molecule Therapeutics Market for Dravet Syndrome, 2021-2030 (USD Million)
Figure 9.11 RNA Targeting Small Molecule Therapeutics Market for Epilepsy, 2021-2030 (USD Million)
Figure 9.12 RNA Targeting Small Molecule Therapeutics Market for HIV Infections, 2021-2030 (USD Million)
Figure 9.13 RNA Targeting Small Molecule Therapeutics Market for Impaired Renal Function, 2021-2030 (USD Million)
Figure 9.14 RNA Targeting Small Molecule Therapeutics Market for Non-Small Cell Lung Cancer, 2021-2030 (USD Million)
Figure 9.15 RNA Targeting Small Molecule Therapeutics Market for Rheumatoid Arthritis, 2021-2030 (USD Million)
Figure 9.16 RNA Targeting Small Molecule Therapeutics Market for Spinal Muscular Atrophy, 2021-2030 (USD Million)
Figure 9.17 RNA Targeting Small Molecule Therapeutics Market for Ulcerative Colitis, 2021-2030 (USD Million)
Figure 9.18 RNA Targeting Small Molecule Therapeutics Market: Distribution by Key Therapeutic Areas, 2021 and 2030
Figure 9.19 RNA Targeting Small Molecule Therapeutics Market for Autoimmune Disorders, 2021-2030 (USD Million)
Figure 9.20 RNA Targeting Small Molecule Therapeutics Market for Genetic Disorders, 2021-2030 (USD Million)
Figure 9.21 RNA Targeting Small Molecule Therapeutics Market for Inflammatory Disorders, 2021-2030 (USD Million)
Figure 9.22 RNA Targeting Small Molecule Therapeutics Market for Infectious Disorders, 2021-2030 (USD Million)
Figure 9.23 RNA Targeting Small Molecule Therapeutics Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 9.24 RNA Targeting Small Molecule Therapeutics Market for Oncological Disorders, 2021-2030 (USD Million)
Figure 9.25 RNA Targeting Small Molecule Therapeutics Market for Ophthalmic Disorders, 2021-2030 (USD Million)
Figure 9.26 RNA Targeting Small Molecule Therapeutics Market for Rare Disorders, 2021-2030 (USD Million)
Figure 9.27 RNA Targeting Small Molecule Therapeutics Market for Renal Disorders, 2021-2030 (USD Million)
Figure 9.28 RNA Targeting Small Molecule Therapeutics Market for Respiratory Disorders, 2021-2030 (USD Million)
Figure 9.29 RNA Targeting Small Molecule Therapeutics Market: Distribution by Target Molecule, 2021 and 2030
Figure 9.30 RNA Targeting Small Molecule Therapeutics Market for CDKL5, 2021-2030 (USD Million)
Figure 9.31 RNA Targeting Small Molecule Therapeutics Market for Cap Binding Complex, 2021-2030 (USD Million)
Figure 9.32 RNA Targeting Small Molecule Therapeutics Market for Dystrophin Protein, 2021-2030 (USD Million)
Figure 9.33 RNA Targeting Small Molecule Therapeutics Market for Estrogen Receptor Alpha, 2021-2030 (USD Million)
Figure 9.34 RNA Targeting Small Molecule Therapeutics Market for G542X, 2021-2030 (USD Million)
Figure 9.35 RNA Targeting Small Molecule Therapeutics Market for MNK1 / MNK2 PAX6 Gene, 2021-2030 (USD Million)
Figure 9.36 RNA Targeting Small Molecule Therapeutics Market for PAX6 Gene, 2021-2030 (USD Million)
Figure 9.37 RNA Targeting Small Molecule Therapeutics Market for SMN2, 2021-2030 (USD Million)
Figure 9.38 RNA Targeting Small Molecule Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
Figure 9.39 RNA Targeting Small Molecule Therapeutics Market for Oral Drugs, 2021-2030 (USD Million)
Figure 9.40 RNA Targeting Small Molecule Therapeutics Market for Subcutaneous Injections, 2021-2030 (USD Million)
Figure 9.41 RNA Targeting Small Molecule Therapeutics Market: Distribution by Geography, 2021 and 2030
Figure 9.42 RNA Targeting Small Molecule Therapeutics Market in North America, 2021-2030 (USD Million)
Figure 9.43 RNA Targeting Small Molecule Therapeutics Market in Europe, 2021-2030 (USD Million)
Figure 9.44 RNA Targeting Small Molecule Therapeutics Market in Asia, 2021-2030 (USD Million)
Figure 9.45 RNA Targeting Small Molecule Therapeutics Market in MENA, 2021-2030 (USD Million)
Figure 9.46 RNA Targeting Small Molecule Therapeutics Market in Latin America, 2021-2030 (USD Million)
Figure 9.47 RNA Targeting Small Molecule Therapeutics Market in Rest of the World, 2021-2030 (USD Million)
Figure 9.48 Translarna (Ataluren, PTC127), PTC Therapeutics, Sales Forecast, till 2030 (USD Million)
Figure 9.49 Risdiplam, PTC Therapeutics, Sales Forecast, till 2030 (USD Million)
Figure 9.50 Tomivosertib (eFT508), eFFECTOR Therapeutics, till 2030 (USD Million)
Figure 9.51 ELX-02, Eloxx Pharmaceuticals, Sales Forecast, till 2030 (USD Million)
Figure 9.52 H3B-6545, H3 Biomedicine, Sales Forecast, till 2030 (USD Million)
Figure 9.53 Translarna (Ataluren, PTC124), PTC Therapeutics, Sales Forecast, till 2030 (USD Million)
Figure 9.54 ABX464 (Monotherapy), Abivax, Sales Forecast, till 2030 (USD Million)
Figure 9.55 ABX464 and Methotrexate, Abivax, Sales Forecast, till 2030 (USD Million)
Figure 9.56 Global RNA Targeting Small Molecule Therapeutics Market, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 10.1 Concluding Remarks: Market Landscape
Figure 10.2 Concluding Remarks: Company Competitiveness and Investment Landscape
Figure 10.3 Concluding Remarks: Recent Collaborations and Partnerships
Figure 10.4 Concluding Remarks: Funding and Investment Analysis
Figure 10.5 Concluding Remarks: Market Sizing and Opportunity Analysis
LIST OF TABLES
Table 4.1 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Information on Phase of Development, Target Disease Indication(s) and Therapeutic Area
Table 4.2 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Information on Target Molecule, Type of Molecule and Type of Therapy
Table 4.3 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Information on Phase of Development, Target Disease Indication(s) and Therapeutic Area
Table 4.4 RNA Targeting Small Molecule Therapeutics: List of Drug Developers
Table 5.1 RNA Targeting Small Molecule Therapeutics Developers: Competitiveness Analysis
Table 5.2 Company Profile: PTC Therapeutics
Table 5.3 Company Profile: AC Immune
Table 5.4 Company Profile: Skyhawk Therapeutics
Table 5.5 Company Profile: Abivax
Table 5.6 Company Profile: eFFECTOR Therapeutics
Table 6.1 List of Companies Profiled
Table 6.2 Abivax: Company Overview
Table 6.3 Abivax: Recent Developments and Future Outlook
Table 6.4 AC Immune: Company Overview
Table 6.5 AC Immune: Recent Developments and Future Outlook
Table 6.6 Arrakis Therapeutics: Company Overview
Table 6.7 Arrakis Therapeutics: Recent Developments and Future Outlook
Table 6.8 eFFECTOR Therapeutics: Company Overview
Table 6.9 eFFECTOR Therapeutics: Recent Developments and Future Outlook
Table 6.10 Eloxx Pharmaceuticals: Company Overview
Table 6.11 Eloxx Pharmaceuticals: Recent Developments and Future Outlook
Table 6.12 H3 Biomedicine: Company Overview
Table 6.13 H3 Biomedicine: Recent Developments and Future Outlook
Table 6.14 PTC Therapeutics: Company Overview
Table 6.15 PTC Therapeutics: Recent Developments and Future Outlook
Table 6.16 Ribometrix: Company Overview
Table 6.17 Ribometrix: Recent Developments and Future Outlook
Table 6.18 Skyhawk Therapeutics: Company Overview
Table 6.19 Skyhawk Therapeutics: Recent Developments and Future Outlook
Table 6.20 STORM Therapeutics: Company Overview
Table 6.21 STORM Therapeutics: Recent Developments and Future Outlook
Table 7.1 RNA Targeting Small Molecule Therapeutics: List of Collaborations, 2017-2021
Table 7.2 Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2017 – 2021
Table 8.1 Funding and Investments: Information on Year of Investment, Type of Funding, Amount and Investor, between 2015 to 2021
Table 8.2 Funding and Investments: Information on Year of Establishment, Location of Headquarters of Recipients, Target Indication, and Therapeutic Area
Table 9.1 RNA Targeting Small Molecule Therapeutics: Promising Drug Candidates
Table 9.2 RNA Targeting Small Molecule Therapeutics Forecast Assumptions: Price Estimations in Key Geographies
Table 9.3 Translarna (Ataluren, PTC127), PTC Therapeutics: Target Patient Population
Table 9.4 Translarna (Ataluren, PTC127), PTC Therapeutics: Net Present Value (USDMillion)
Table 9.5 Translarna (Ataluren, PTC127), PTC Therapeutics: Value Creation Analysis (USDMillion)
Table 9.6 Risdiplam, PTC Therapeutics: Target Patient Population
Table 9.7 Risdiplam, PTC Therapeutics: Net Present Value (USDMillion)
Table 9.8 Risdiplam, PTC Therapeutics: Value Creation Analysis (USDMillion)
Table 9.9 Tomivosertib (eFT508), eFFECTOR Therapeutics: Target Patient Population
Table 9.10 Tomivosertib (eFT508), eFFECTOR Therapeutics: Net Present Value (USDMillion)
Table 9.11 Tomivosertib (eFT508), eFFECTOR Therapeutics: Value Creation Analysis (USDMillion)
Table 9.12 ELX-02, Eloxx Pharmaceuticals: Target Patient Population
Table 9.13 ELX-02, Eloxx Pharmaceuticals: Net Present Value (USDMillion)
Table 9.14 ELX-02, Eloxx Pharmaceuticals: Value Creation Analysis (USDMillion)
Table 9.15 H3B-6545, H3 Biomedicine: Target Patient Population
Table 9.16 H3B-6545, H3 Biomedicine: Net Present Value (USDMillion)
Table 9.17 H3B-6545, H3 Biomedicine: Value Creation Analysis (USDMillion)
Table 9.18 Translarna (Ataluren, PTC124), PTC Therapeutics: Target Patient Population
Table 9.19 Translarna (Ataluren, PTC124), PTC Therapeutics: Net Present Value (USDMillion)
Table 9.20 Translarna (Ataluren, PTC124), PTC Therapeutics: Value Creation Analysis (USDMillion)
Table 9.21 ABX464 (Monotherapy), Abivax: Target Patient Population
Table 9.22 ABX464 (Monotherapy), Abivax: Net Present Value (USDMillion)
Table 9.23 ABX464 (Monotherapy), Abivax: Value Creation Analysis (USDMillion)
Table 9.24 ABX464 and Methotrexate, Abivax: Target Patient Population
Table 9.25 ABX464 and Methotrexate, Abivax: Net Present Value (USDMillion)
Table 9.26 ABX464 and Methotrexate, Abivax: Value Creation Analysis (USDMillion)
Table 11.1. Anima Biotech: Company Snapshot
Table 11.2. Novation Pharmaceuticals: Company Snapshot
Table 12.1 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development
Table 12.2 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.3 RNA Targeting Small Molecule Therapeutics (Clinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Table 12.4 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Therapeutic Area
Table 12.5 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.6 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Target Molecule
Table 12.7 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development and Target Molecule
Table 12.8 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Type of Approach
Table 12.9 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Phase of Development Type of Approach
Table 12.10 RNA Targeting Small Molecule Therapeutics (Clinical-stage and Marketed Drug Candidates): Distribution by Route of Administration
Table 12.11 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development
Table 12.12 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Disease Indication(s)
Table 12.13 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Disease Indication(s)
Table 12.14 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Therapeutic Area
Table 12.15 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Therapeutic Area
Table 12.16 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Target Molecule
Table 12.17 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development and Target Molecule
Table 12.18 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Type of Approach
Table 12.19 RNA Targeting Small Molecule Therapeutics (Preclinical-stage Drug Candidates): Distribution by Phase of Development Type of Approach
Table 12.20 RNA Targeting small molecule therapeutics Developers: Distribution by Year of Establishment
Table 12.21 RNA Targeting small molecule therapeutics Developers: Distribution by Company Size
Table 12.22 RNA Targeting Small Molecule Therapeutics Developers: Distribution by Location of Headquarters
Table 12.23 Leading Developers: Analysis by Number of Proprietary Drug Candidates
Table 12.24 Recent Collaborations and Partnerships: Cumulative Year-Wise Trend, 2017 – 2021 (till May)
Table 12.25 Recent Collaborations and Partnerships: Distribution by Type of Partnership
Table 12.26 Recent Collaborations and Partnerships: Distribution by Year and Type of Partnership
Table 12.27 Recent Collaborations and Partnerships: Distribution by Type of Target Indication(s)
Table 12.28 Recent Collaborations and Partnerships: Distribution by Type of Partnership and Target Indication(s)
Table 12.29 Recent Collaborations and Partnerships: Distribution by Therapeutic Area
Table 12.30 Recent Collaborations and Partnerships: Distribution by Type of Partnership and Therapeutic Area
Table 12.31 Recent Collaborations and Partnerships: Distribution by Number of Partnerships
Table 12.32 Recent Collaborations and Partnerships: Distribution by Partner Headquarters
Table 12.33 Recent Collaborations and Partnerships: Country-wise Distribution
Table 12.34 Recent Collaborations and Partnerships: Region-wise Distribution
Table 12.35 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2015 - 2021
Table 12.36 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2015- 2021
Table 12.37 Funding and Investment Analysis: Distribution by Type of Funding, 2015- 2021
Table 12.38 Funding and Investment Analysis: Year-Wise Distribution by Type of Funding, 2015- 2021
Table 12.39 Funding and Investment Analysis: Distribution of Total Amount Invested (USD Million) by Type of Funding, 2015- 2021
Table 12.40 Funding and Investment Analysis: Summary of Amount Invested, 2015- 2021
Table 12.41 Funding and Investment Analysis: Distribution by Therapeutic Area, 2015-2021 (USD Million)
Table 12.42 Funding and Investment Analysis: Distribution of Total Amount Invested (USD Million) by Therapeutic Area, 2015-2021
Table 12.43 Funding and Investment Analysis: Distribution by Phase of Development and Total Amount Invested (USD Million)
Table 12.44 Global RNA Targeting Small Molecule Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.45 RNA Targeting Small Molecule Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
Table 12.46 RNA Targeting Small Molecule Therapeutics Market for Aniridia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.47 RNA Targeting Small Molecule Therapeutics Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.48 RNA Targeting Small Molecule Therapeutics Market for Castrate-resistant Prostate Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.49 RNA Targeting Small Molecule Therapeutics Market for Colorectal Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.50 RNA Targeting Small Molecule Therapeutics Market for Crohn Disease, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.51 RNA Targeting Small Molecule Therapeutics Market for Cystic Fibrosis, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.52 RNA Targeting Small Molecule Therapeutics Market for Duchenne Muscular Dystrophy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.53 RNA Targeting Small Molecule Therapeutics Market for Dravet Syndrome, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.54 RNA Targeting Small Molecule Therapeutics Market for Epilepsy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.55 RNA Targeting Small Molecule Therapeutics Market for HIV Infections, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.56 RNA Targeting Small Molecule Therapeutics Market for Impaired Renal Function, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.57 RNA Targeting Small Molecule Therapeutics Market for Non-Small Cell Lung Cancer, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.58 RNA Targeting Small Molecule Therapeutics Market for Rheumatoid Arthritis, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.59 RNA Targeting Small Molecule Therapeutics Market for Spinal Muscular Atrophy, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.60 RNA Targeting Small Molecule Therapeutics Market for Ulcerative Colitis, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.61 RNA Targeting Small Molecule Therapeutics Market: Distribution by Key Therapeutic Areas, 2021 and 2030
Table 12.62 RNA Targeting Small Molecule Therapeutics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.63 RNA Targeting Small Molecule Therapeutics Market for Genetic Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.64 RNA Targeting Small Molecule Therapeutics Market for Inflammatory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.65 RNA Targeting Small Molecule Therapeutics Market for Infectious Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.66 RNA Targeting Small Molecule Therapeutics Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.67 RNA Targeting Small Molecule Therapeutics Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.68 RNA Targeting Small Molecule Therapeutics Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.69 RNA Targeting Small Molecule Therapeutics Market for Rare Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.70 RNA Targeting Small Molecule Therapeutics Market for Renal Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.71 RNA Targeting Small Molecule Therapeutics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.72 RNA Targeting Small Molecule Therapeutics Market: Distribution by by Target Molecule, 2021 and 2030
Table 12.73 RNA Targeting Small Molecule Therapeutics Market for CDKL5, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.74 RNA Targeting Small Molecule Therapeutics Market for Cap Binding Complex, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.75 RNA Targeting Small Molecule Therapeutics Market for Dystrophin Protein, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.76 RNA Targeting Small Molecule Therapeutics Market for Estrogen Receptor Alpha, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.77 RNA Targeting Small Molecule Therapeutics Market for G542X, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.78 RNA Targeting Small Molecule Therapeutics Market for MNK1 / MNK2 PAX6 Gene, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.79 RNA Targeting Small Molecule Therapeutics Market for PAX6 Gene, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.80 RNA Targeting Small Molecule Therapeutics Market for SMN2, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.81 RNA Targeting Small Molecule Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
Table 12.82 RNA Targeting Small Molecule Therapeutics Market for Oral Drugs, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.83 RNA Targeting Small Molecule Therapeutics Market for Subcutaneous Injections, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.84 RNA Targeting Small Molecule Therapeutics Market: Distribution by Geography, 2021 and 2030
Table 12.85 RNA Targeting Small Molecule Therapeutics Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.86 RNA Targeting Small Molecule Therapeutics Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.87 RNA Targeting Small Molecule Therapeutics Market in Asia, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.88 RNA Targeting Small Molecule Therapeutics Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.89 RNA Targeting Small Molecule Therapeutics Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.90 RNA Targeting Small Molecule Therapeutics Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.91 Translarna (Ataluren, PTC127), PTC Therapeutics, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.92 Risdiplam, PTC Therapeutics, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.93 Tomivosertib (eFT508), eFFECTOR Therapeutics, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.94 ELX-02, Eloxx Pharmaceuticals, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.95 H3B-6545, H3 Biomedicine, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.96 Translarna (Ataluren, PTC124), PTC Therapeutics, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.97 ABX464 (Monotherapy), Abivax, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.98 ABX464 and Methotrexate, Abivax, Sales Forecast, till 2030 Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 12.99 Global RNA Targeting Small Molecule Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook